NanoCure AI Company

NanoCure AI Company (Incorporated in Texas, 2025) is pioneering the world's first closed-loop therapeutic and diagnostic platform designed to detect and eliminate harmful or diseased cells in real time. Our mission is simple yet transformative: to heal without harm. We are developing an extracorporeal system that integrates microscopy, fluidics, machine learning, and nanotechnology to classify, isolate, and neutralize malignant or abnormal blood cells without drugs, dyes, or radiation. Our platform operates through two core systems: Affinity-Based System: Targets and removes circulating tumor cells (CTCs) using functionalized nanoparticles, AI-guided imaging, and electromagnetic actuation to prevent metastatic spread. Affinity-Independent System: Detects and filters hematologic abnormalities such as sickle cells, leukemic blasts (AML, ALL, CML), and lymphoma-related malignant cells through real-time optical and morphological classification using AI-enhanced microscopy. Both systems function within a closed-loop architecture that continuously senses, interprets, acts, and validates results to maintain healthy blood composition while providing actionable feedback to clinicians. Why It Matters: Metastasis, hematologic malignancies, and chronic blood disorders remain among the most challenging and deadly conditions. Existing treatments manage symptoms but rarely target the bloodstream itself. NanoCure AI introduces a new therapeutic category: real-time extracorporeal precision therapy that integrates detection and intervention in a single continuous cycle. Our Expertise: Our founding and advisory team brings over 110 years of experience, 40 issued patents, and 150+ publications spanning medical imaging, oncology, nanomaterials, and AI diagnostics. Collectively, they have launched FDA-cleared imaging systems, led global oncology trials, and built nanorobotic and AI architectures that now form the foundation of NanoCure AI's technology.

• Employees 3